OncoSec Medical Inc. (OTCQB:ONCS), a company developing its
advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy
to treat solid tumors, has announced it will be presenting at the 2013
Aegis Capital Healthcare Conference. The presentation will take place
at 9:45am PT on Thursday, September 26 at The Encore at Wynn in Las
Vegas, NV.
Punit Dhillon, President and CEO of OncoSec Medical, will provide a
company overview and will be available to participate in one-on-one
meetings with investors who are registered to attend the conference.
About the 2013 Aegis Capital Healthcare Conference
This symposium, hosted by Aegis Capital Corp., will feature
presentations from industry-leading growth companies in the healthcare
sector.
The executives presenting at the conference come from the highest ranks
of management and the most innovative aspects of science. They will be
offering views into their companies and into the healthcare industry as
a whole. Following corporate presentations, executives will have the
opportunity to participate in question-and-answer sessions with fund
managers, institutional and private investors, industry analysts, and
Aegis Capital’s top-performing brokers.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its
advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy
to treat solid tumors. ImmunoPulse and NeoPulse therapies address an
unmet medical need and represent a potential solution, for less invasive
and less expensive therapies that are able to minimize detrimental
effects resulting from currently available cancer treatments such as
surgery, systemic chemotherapy or immunotherapy and other treatment
alternatives. OncoSec Medical's core technology is based upon its
proprietary use of an electroporation platform to enhance the delivery
and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse)
or chemotherapeutic agent (NeoPulse). Treatment of various solid
cancers using these targeted anti-cancer agents has
demonstrated selective destruction of cancerous cells while potentially
sparing healthy normal tissues during early and late stage clinical
trials. OncoSec's clinical programs include three Phase II clinical
trials for ImmunoPulse targeting lethal skin cancers. More information
is available at http://www.oncosec.com/.
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this release that are not historical facts may be
considered such "forward-looking statements." Forward-looking statements
are based on management's current preliminary expectations and are
subject to risks and uncertainties which may cause our results to differ
materially and adversely from the statements contained herein. Some of
the potential risks and uncertainties that could cause actual results to
differ from those predicted include our ability to raise additional
funding, our ability to acquire, develop or commercialize new products,
uncertainties inherent in pre-clinical studies and clinical trials,
unexpected new data, safety and technical issues, competition and market
conditions. These and additional risks and uncertainties are more fully
described in OncoSec Medical's filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances after the
date they are made, or to reflect the occurrence of unanticipated events.
Copyright Business Wire 2013